Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies

Subjects will have been recently diagnosed with an untreated hematologic malignancy. Subjects
will have a blood sample collected at enrollment and provide medical history prior to
initiation of treatment. There will be no further follow-up.

Inclusion Criteria:

- Subject is male or female ≥ 18 years of age.

- Subject has an untreated hematologic malignancy.

- Subject understands the study procedures and is able to provide informed consent to
participate in the study and authorization for release of relevant protected health
information to the study Investigator.

Exclusion Criteria:

- Any previous cancer diagnosis within the past 5 years (with the exceptions of basal
cell or squamous cell skin cancers).

- Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample
collection.

- Any treatment for the primary malignancy. Subject may not have started neo-adjuvant
chemotherapy, neo-adjuvant radiation therapy, immunotherapy or other treatment prior
to blood sample collection.

- Less than 3 days between fine needle aspiration (FNA) of target pathology and blood
collection.

- Less than 7 days between biopsy (other than FNA) of target pathology and blood
collection.

- IV contrast (e.g. CT and MRI) within 1 day [or 24 hours] of blood collection.

- Individual has a condition the Investigator believes would interfere with his or her
ability to provide informed consent, comply with the study protocol, which might
confound the interpretation of the study results or put the person at undue risk.